MedPath

Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI

Phase 1
Terminated
Conditions
Pregnancy
Interventions
Registration Number
NCT02510534
Lead Sponsor
Northwest Center for Infertility and Reproductive Endocrinology
Brief Summary

To determine the difference in clinical pregnancy rates with and without luteal progesterone support in a young reproductive aged population having undergone ovulation induction with combined clomiphene citrate and gonadotropin protocol with intrauterine insemination.

Detailed Description

To determine the difference in clinical pregnancy rates with and without luteal progesterone support in a young reproductive aged population having undergone ovulation induction with combined clomiphene citrate and gonadotropin protocol with intrauterine insemination.

Patients will be randomized in a treatment arm or control arm. The treatment arm receives the luteal progesterone support and the control arm does not. Each arm will have 260 patients.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
520
Inclusion Criteria
  • Age 18-37
  • BMI 19-34 kg/m2
  • Day 2-3 Follicle stimulating hormone (FSH) less than 10IU/mL
  • Estradiol (E2) less than 80 pg/mL
  • Anti-mullerian hormone (AMH) more than 1.5 ng/mL; or antral follicle count (AFC) up to 10
  • Two patent fallopian tubes confirmed by hysterosalpingogram (HSG) or chromopertubation
  • Normal uterine cavity confirmed by HSG, saline sonohysterogram (SIS) or hysteroscopy
Exclusion Criteria
  • Severe male factor (total count less than 10 million sperm)
  • Systemic diseases not limited to diabetes
  • Pregnancy within 3 months
  • More than 1 prior cycle of gonadotropin treatment
  • Any ovarian cyst >15mm that has persisted for > 1 month
  • Endometrioma and/or Endometriosis-stage III or IV
  • Submucosal uterine fibroids; untreated endometrial polyps >1 cm;abnormal reproductive tract bleeding
  • Intolerance or allergy to study drug
  • Substance abuse (including alcohol and tobacco)
  • History of chemotherapy (except for gestational conditions) or radiotherapy
  • Minors and those adults not capable of consenting on their own

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlMenopur 150 international unitsThis arm receives Menopur 150 international units x 1 dose
TreatmentMenopur 150 international unitsThis arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
TreatmentEndometrin 100 mgThis arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
Primary Outcome Measures
NameTimeMethod
Effect on Pregnancy rate measured by detectable embryonic cardiac activity10 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ivf Florida

🇺🇸

Margate, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath